Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia

Deborah A. Thomas, Andreas H. Sarris, Jorge Cortes, Stefan Faderl, Susan O'Brien, Francis J. Giles, Guillermo Garcia-Manero, Maria A. Rodriguez, Fernando Cabanillas, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Outcomes with salvage therapy for patients with recurrent or refractory acute lymphocytic leukemia (ALL) are poor, with complete response (CR) rates reported to be 20-30% and a median survival ranging from 2-6 months. New agents are needed to reduce the recurrence rate after frontline chemotherapy. Vincristine is an important component of ALL therapy. In animal models, the encapsulation of vincristine into sphingomyelin liposomes or "sphingosomes" for injection (SV) has improved efficacy compared with conventional vincristine. METHODS. A Phase II clinical trial of single-agent SV given at a dose of 2.0 mg/m2 every 2 weeks was conducted in patients with recurrent or refractory ALL. Approximately half of the 16 patients who received SV had a first CR duration of less than 1 year, 19% had failed standard induction chemotherapy, and 50% had Philadelphia chromosome-positive disease. SV was the first salvage attempt in 69% of the patients. RESULTS. The overall response rate in the 14 evaluable patients was 14% (1 CR and 1 partial response). Five patients (36%) had transient reductions in bone marrow leukemia infiltrate with subsequent regrowth of the leukemia between SV infusions. Toxicity with limited treatment (median number of doses was two; range, one to five doses) was minimal with expected peripheral neuropathy. CONCLUSIONS. Further study of SV in patients with ALL is warranted. A Phase I-II clinical trial of weekly SV with pulse dexamethasone currently is ongoing.

Original languageEnglish (US)
Pages (from-to)120-127
Number of pages8
JournalCancer
Volume106
Issue number1
DOIs
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Vincristine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase II Clinical Trials
Leukemia
Salvage Therapy
Philadelphia Chromosome
Clinical Trials, Phase I
Induction Chemotherapy
Sphingomyelins
Peripheral Nervous System Diseases
Liposomes
Dexamethasone
Animal Models
Bone Marrow
Recurrence
Drug Therapy
Injections
Survival
Therapeutics

Keywords

  • Acute lymphoblastic leukemia (ALL)
  • Chemotherapy
  • Salvage
  • Sphingosomal vincristine (SV)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Thomas, D. A., Sarris, A. H., Cortes, J., Faderl, S., O'Brien, S., Giles, F. J., ... Kantarjian, H. (2006). Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer, 106(1), 120-127. https://doi.org/10.1002/cncr.21595

Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. / Thomas, Deborah A.; Sarris, Andreas H.; Cortes, Jorge; Faderl, Stefan; O'Brien, Susan; Giles, Francis J.; Garcia-Manero, Guillermo; Rodriguez, Maria A.; Cabanillas, Fernando; Kantarjian, Hagop.

In: Cancer, Vol. 106, No. 1, 01.01.2006, p. 120-127.

Research output: Contribution to journalArticle

Thomas, DA, Sarris, AH, Cortes, J, Faderl, S, O'Brien, S, Giles, FJ, Garcia-Manero, G, Rodriguez, MA, Cabanillas, F & Kantarjian, H 2006, 'Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia', Cancer, vol. 106, no. 1, pp. 120-127. https://doi.org/10.1002/cncr.21595
Thomas, Deborah A. ; Sarris, Andreas H. ; Cortes, Jorge ; Faderl, Stefan ; O'Brien, Susan ; Giles, Francis J. ; Garcia-Manero, Guillermo ; Rodriguez, Maria A. ; Cabanillas, Fernando ; Kantarjian, Hagop. / Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. In: Cancer. 2006 ; Vol. 106, No. 1. pp. 120-127.
@article{db41a1b0432f4b03bb9e47c486cb7a3b,
title = "Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia",
abstract = "BACKGROUND. Outcomes with salvage therapy for patients with recurrent or refractory acute lymphocytic leukemia (ALL) are poor, with complete response (CR) rates reported to be 20-30{\%} and a median survival ranging from 2-6 months. New agents are needed to reduce the recurrence rate after frontline chemotherapy. Vincristine is an important component of ALL therapy. In animal models, the encapsulation of vincristine into sphingomyelin liposomes or {"}sphingosomes{"} for injection (SV) has improved efficacy compared with conventional vincristine. METHODS. A Phase II clinical trial of single-agent SV given at a dose of 2.0 mg/m2 every 2 weeks was conducted in patients with recurrent or refractory ALL. Approximately half of the 16 patients who received SV had a first CR duration of less than 1 year, 19{\%} had failed standard induction chemotherapy, and 50{\%} had Philadelphia chromosome-positive disease. SV was the first salvage attempt in 69{\%} of the patients. RESULTS. The overall response rate in the 14 evaluable patients was 14{\%} (1 CR and 1 partial response). Five patients (36{\%}) had transient reductions in bone marrow leukemia infiltrate with subsequent regrowth of the leukemia between SV infusions. Toxicity with limited treatment (median number of doses was two; range, one to five doses) was minimal with expected peripheral neuropathy. CONCLUSIONS. Further study of SV in patients with ALL is warranted. A Phase I-II clinical trial of weekly SV with pulse dexamethasone currently is ongoing.",
keywords = "Acute lymphoblastic leukemia (ALL), Chemotherapy, Salvage, Sphingosomal vincristine (SV)",
author = "Thomas, {Deborah A.} and Sarris, {Andreas H.} and Jorge Cortes and Stefan Faderl and Susan O'Brien and Giles, {Francis J.} and Guillermo Garcia-Manero and Rodriguez, {Maria A.} and Fernando Cabanillas and Hagop Kantarjian",
year = "2006",
month = "1",
day = "1",
doi = "10.1002/cncr.21595",
language = "English (US)",
volume = "106",
pages = "120--127",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia

AU - Thomas, Deborah A.

AU - Sarris, Andreas H.

AU - Cortes, Jorge

AU - Faderl, Stefan

AU - O'Brien, Susan

AU - Giles, Francis J.

AU - Garcia-Manero, Guillermo

AU - Rodriguez, Maria A.

AU - Cabanillas, Fernando

AU - Kantarjian, Hagop

PY - 2006/1/1

Y1 - 2006/1/1

N2 - BACKGROUND. Outcomes with salvage therapy for patients with recurrent or refractory acute lymphocytic leukemia (ALL) are poor, with complete response (CR) rates reported to be 20-30% and a median survival ranging from 2-6 months. New agents are needed to reduce the recurrence rate after frontline chemotherapy. Vincristine is an important component of ALL therapy. In animal models, the encapsulation of vincristine into sphingomyelin liposomes or "sphingosomes" for injection (SV) has improved efficacy compared with conventional vincristine. METHODS. A Phase II clinical trial of single-agent SV given at a dose of 2.0 mg/m2 every 2 weeks was conducted in patients with recurrent or refractory ALL. Approximately half of the 16 patients who received SV had a first CR duration of less than 1 year, 19% had failed standard induction chemotherapy, and 50% had Philadelphia chromosome-positive disease. SV was the first salvage attempt in 69% of the patients. RESULTS. The overall response rate in the 14 evaluable patients was 14% (1 CR and 1 partial response). Five patients (36%) had transient reductions in bone marrow leukemia infiltrate with subsequent regrowth of the leukemia between SV infusions. Toxicity with limited treatment (median number of doses was two; range, one to five doses) was minimal with expected peripheral neuropathy. CONCLUSIONS. Further study of SV in patients with ALL is warranted. A Phase I-II clinical trial of weekly SV with pulse dexamethasone currently is ongoing.

AB - BACKGROUND. Outcomes with salvage therapy for patients with recurrent or refractory acute lymphocytic leukemia (ALL) are poor, with complete response (CR) rates reported to be 20-30% and a median survival ranging from 2-6 months. New agents are needed to reduce the recurrence rate after frontline chemotherapy. Vincristine is an important component of ALL therapy. In animal models, the encapsulation of vincristine into sphingomyelin liposomes or "sphingosomes" for injection (SV) has improved efficacy compared with conventional vincristine. METHODS. A Phase II clinical trial of single-agent SV given at a dose of 2.0 mg/m2 every 2 weeks was conducted in patients with recurrent or refractory ALL. Approximately half of the 16 patients who received SV had a first CR duration of less than 1 year, 19% had failed standard induction chemotherapy, and 50% had Philadelphia chromosome-positive disease. SV was the first salvage attempt in 69% of the patients. RESULTS. The overall response rate in the 14 evaluable patients was 14% (1 CR and 1 partial response). Five patients (36%) had transient reductions in bone marrow leukemia infiltrate with subsequent regrowth of the leukemia between SV infusions. Toxicity with limited treatment (median number of doses was two; range, one to five doses) was minimal with expected peripheral neuropathy. CONCLUSIONS. Further study of SV in patients with ALL is warranted. A Phase I-II clinical trial of weekly SV with pulse dexamethasone currently is ongoing.

KW - Acute lymphoblastic leukemia (ALL)

KW - Chemotherapy

KW - Salvage

KW - Sphingosomal vincristine (SV)

UR - http://www.scopus.com/inward/record.url?scp=29744456024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29744456024&partnerID=8YFLogxK

U2 - 10.1002/cncr.21595

DO - 10.1002/cncr.21595

M3 - Article

C2 - 16331634

AN - SCOPUS:29744456024

VL - 106

SP - 120

EP - 127

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -